3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence
Executive Summary
3M is betting big on wound-care maker Acelity and paying $6.7bn to buy the company and its KCI subsidiaries in its largest acquisition to date.
You may also be interested in...
3M Plans To Spin Off Health Care Business By The End Of 2023
The company’s health businesses include product lines worth nearly $9bn in annual sales. The deal is designed to allow both the new health care company and the “new 3M” to focus resources more efficiently on their separate priorities.
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
KCI's Prevena Becomes First FDA-Cleared Negative Pressure Wound-Closure Device
The US FDA granted KCI's de novo request for the Prevena incision management system, making it the first negative pressure device cleared for reducing superficial surgical site infections in patients at high risk.